BUFFALO, N.Y. — University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication, often described as a wonder drug, ...
iX Biopharma is transforming approved drugs such as ketamine into novel therapies using its wafer-based sublingual technology, to develop therapies for pain, depression and more. Since its ...